40 related articles for article (PubMed ID: 20091489)
1. A fast and efficient liquid chromatography-tandem mass spectrometry method for measuring l- and d-amino acids in the urine of patients with immunoglobulin A nephropathy.
Zha Z; Wang R; Wang Q; Chen F; Ye Z; Li Y
Biomed Chromatogr; 2024 Jun; 38(6):e5866. PubMed ID: 38618866
[TBL] [Abstract][Full Text] [Related]
2. Implications of O-glycan modifications in the hinge region of a plant-produced SARS-CoV-2-IgA antibody on functionality.
Uetz P; Göritzer K; Vergara E; Melnik S; Grünwald-Gruber C; Figl R; Deghmane AE; Groppelli E; Reljic R; Ma JK; Stöger E; Strasser R
Front Bioeng Biotechnol; 2024; 12():1329018. PubMed ID: 38511130
[No Abstract] [Full Text] [Related]
3. Sublancin is not a lantibiotic but an S-linked glycopeptide.
Oman TJ; Boettcher JM; Wang H; Okalibe XN; van der Donk WA
Nat Chem Biol; 2011 Feb; 7(2):78-80. PubMed ID: 21196935
[TBL] [Abstract][Full Text] [Related]
4. IgG deposits in the mesangium and capillary loops predict poor renal outcome in patients with IgA nephropathy: a single-center retrospective study.
Peng S; Lu W; Jiang X; Xu X; Wu Y
Ren Fail; 2020 Nov; 42(1):902-911. PubMed ID: 32869693
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry for the identification and analysis of highly complex glycosylation of therapeutic or pathogenic proteins.
Ohyama Y; Nakajima K; Renfrow MB; Novak J; Takahashi K
Expert Rev Proteomics; 2020 Apr; 17(4):275-296. PubMed ID: 32406805
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy.
Novak J; Barratt J; Julian BA; Renfrow MB
Semin Nephrol; 2018 Sep; 38(5):461-476. PubMed ID: 30177018
[TBL] [Abstract][Full Text] [Related]
7. Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
Sun Q; Zhang Z; Zhang H; Liu X
PLoS One; 2016; 11(11):e0166700. PubMed ID: 27870872
[TBL] [Abstract][Full Text] [Related]
8. New Insights into the Pathogenesis of IgA Nephropathy.
Novak J; Rizk D; Takahashi K; Zhang X; Bian Q; Ueda H; Ueda Y; Reily C; Lai LY; Hao C; Novak L; Huang ZQ; Renfrow MB; Suzuki H; Julian BA
Kidney Dis (Basel); 2015 May; 1(1):8-18. PubMed ID: 26568951
[TBL] [Abstract][Full Text] [Related]
9. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals.
Lehoux S; Mi R; Aryal RP; Wang Y; Schjoldager KT; Clausen H; van Die I; Han Y; Chapman AB; Cummings RD; Ju T
Mol Cell Proteomics; 2014 Nov; 13(11):3097-113. PubMed ID: 25071157
[TBL] [Abstract][Full Text] [Related]
10. The genetics and immunobiology of IgA nephropathy.
Kiryluk K; Novak J
J Clin Invest; 2014 Jun; 124(6):2325-32. PubMed ID: 24892706
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy.
Berthoux F; Suzuki H; Thibaudin L; Yanagawa H; Maillard N; Mariat C; Tomino Y; Julian BA; Novak J
J Am Soc Nephrol; 2012 Sep; 23(9):1579-87. PubMed ID: 22904352
[TBL] [Abstract][Full Text] [Related]
12. The pathophysiology of IgA nephropathy.
Suzuki H; Kiryluk K; Novak J; Moldoveanu Z; Herr AB; Renfrow MB; Wyatt RJ; Scolari F; Mestecky J; Gharavi AG; Julian BA
J Am Soc Nephrol; 2011 Oct; 22(10):1795-803. PubMed ID: 21949093
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometry based glycoproteomics--from a proteomics perspective.
Pan S; Chen R; Aebersold R; Brentnall TA
Mol Cell Proteomics; 2011 Jan; 10(1):R110.003251. PubMed ID: 20736408
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the specific structures of IgA1 hinge glycopeptide in 30 IgA nephropathy patients by mass spectrometry.
Odani H; Yamamoto K; Iwayama S; Iwase H; Takasaki A; Takahashi K; Fujita Y; Sugiyama S; Hiki Y
J Nephrol; 2010; 23(1):70-6. PubMed ID: 20091489
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometry analysis of IgA1 hinge region in patients with IgA nephropathy.
Gastaldi D; Paradisi L; Baiocchi C; Medana C; Lo Duca G; Sena LM; Roccatello D
J Nephrol; 2007; 20(6):689-95. PubMed ID: 18046671
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence for decreased sialylation and galactosylation of human serum IgA1 Fc O-glycosylated hinge peptides in IgA nephropathy by mass spectrometry.
Odani H; Hiki Y; Takahashi M; Nishimoto A; Yasuda Y; Iwase H; Shinzato T; Maeda K
Biochem Biophys Res Commun; 2000 Apr; 271(1):268-74. PubMed ID: 10777713
[TBL] [Abstract][Full Text] [Related]
17. Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy.
Shimozato S; Hiki Y; Odani H; Takahashi K; Yamamoto K; Sugiyama S
Nephrol Dial Transplant; 2008 Jun; 23(6):1931-9. PubMed ID: 18178603
[TBL] [Abstract][Full Text] [Related]
18. Structural features of IgA molecules which contribute to IgA nephropathy.
Feehally J; Allen AC
J Nephrol; 1999; 12(2):59-65. PubMed ID: 10378660
[TBL] [Abstract][Full Text] [Related]
19. Methodological approaches to the analysis of IgA1 O-glycosylation in IgA nephropathy.
Allen AC
J Nephrol; 1999; 12(2):76-84. PubMed ID: 10378662
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
